Legato Capital Management LLC Sells 6,597 Shares of LeMaitre Vascular, Inc. $LMAT

Legato Capital Management LLC lowered its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 48.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,922 shares of the medical instruments supplier’s stock after selling 6,597 shares during the period. Legato Capital Management LLC’s holdings in LeMaitre Vascular were worth $561,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Congress Asset Management Co. lifted its stake in LeMaitre Vascular by 5.8% in the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after acquiring an additional 40,065 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in LeMaitre Vascular in the third quarter valued at $6,056,000. Annex Advisory Services LLC lifted its stake in LeMaitre Vascular by 6.0% in the fourth quarter. Annex Advisory Services LLC now owns 243,709 shares of the medical instruments supplier’s stock valued at $19,765,000 after acquiring an additional 13,692 shares during the last quarter. Wakefield Asset Management LLLP acquired a new stake in LeMaitre Vascular in the fourth quarter valued at $1,130,000. Finally, M&T Bank Corp lifted its stake in LeMaitre Vascular by 2,240.5% in the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after acquiring an additional 381,061 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Insider Activity at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the sale, the director owned 3,942 shares in the company, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO George W. Lemaitre sold 27,881 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 269,891 shares of company stock worth $28,969,086. 7.40% of the stock is owned by corporate insiders.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $98.71 on Wednesday. The firm has a 50-day moving average of $108.17 and a 200-day moving average of $95.53. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The stock has a market cap of $2.26 billion, a PE ratio of 36.42, a P/E/G ratio of 2.72 and a beta of 0.60. LeMaitre Vascular, Inc. has a 52-week low of $79.00 and a 52-week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. The company had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. LeMaitre Vascular’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 36.90%.

Analysts Set New Price Targets

LMAT has been the subject of a number of recent analyst reports. Citizens Jmp increased their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Weiss Ratings upgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 20th. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Wells Fargo & Company increased their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.